PF-431396

PF-431396 is a potent, orally active, small molecule dual inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2), with IC50 values of approximately 2 nM and 11 nM, respectively. Developed by Pfizer, the compound competitively binds to the ATP-binding sites of FAK and PYK2, blocking their phosphorylation and downstream signaling involved in cellular adhesion, migration, and survival. In preclinical studies, PF-431396 has been shown to reduce cancer cell migration, invasion, and proliferation, and suppress tumor cell adhesion and motility across various cancer models, including malignant pleural mesothelioma and pancreatic ductal adenocarcinoma. It has also been investigated in the context of inflammatory bowel disease (Crohn's disease) due to PYK2's role as a risk locus for intestinal inflammation, and has demonstrated bone-anabolic effects in osteoporosis models. PF-431396 is strictly a research compound and is not approved for human or veterinary use.

Other names

PF-431396 hydratePF431396 hydratePF 431396 hydratePF431396PF-431396PF 431396